Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1999;34:907-913

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Intengan, H. D.
Right arrow Articles by Schiffrin, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Intengan, H. D.
Right arrow Articles by Schiffrin, E. L.

(Hypertension. 1999;34:907-913.)
© 1999 American Heart Association, Inc.


Scientific Contributions

Blood Pressure and Small Arteries in DOCA-Salt–Treated Genetically AVP-Deficient Rats

Role of Endothelin

Hope D. Intengan; Jeong Bae Park; Ernesto L. Schiffrin

From the MRC Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, Quebec, Canada.

Correspondence to Ernesto L. Schiffrin, MD, PhD, FRCPC, Clinical Research Institute of Montreal, 110 Pine Ave W, Montreal, Quebec, Canada H2W 1R7. E-mail schiffe{at}IRCM.qc.ca

Abstract—Hypertension is associated with structural and mechanical abnormalities of resistance arteries. We have recently reported that vasopressin may be involved in the blood pressure elevation and remodeling of resistance arteries in deoxycorticosterone acetate (DOCA)-salt hypertension, perhaps by modulating vascular endothelin-1 expression. We tested this hypothesis further by examining DOCA-salt hypertension in homozygous vasopressin-deficient Brattleboro (BB) rats in comparison with Long-Evans (LE; control) rats. Mesenteric resistance arteries (lumen <300 µm) were studied on pressurized myographs. After 5 weeks, systolic blood pressure was greater in LE DOCA-salt–treated rats (189±5 mm Hg) compared with uniephrectomized (UNx) LE control rats (117±4 mm Hg; P<0.01). The increase in blood pressure induced by DOCA-salt treatment was attenuated in vasopressin-deficient rats, such that BB DOCA-salt–treated rats exhibited only a slight elevation of blood pressure (134±6 mm Hg) compared with BB-UNx rats (111±4 mm Hg; P<0.05). Resistance arteries in LE DOCA-salt–treated rats had a smaller lumen diameter and a larger media width, media cross-sectional area, and media-lumen ratio compared with LE-UNx rats. Isobaric stiffness was unaltered in resistance arteries from LE DOCA-salt–treated rats, despite stiffening of the arterial wall components as indicated by a significant increase in the slope of the media stress–incremental elastic modulus relationship. DOCA-salt treatment in the absence of endogenous vasopressin, ie, in homozygous di/di BB rats, failed to alter vascular structure or wall component stiffness and resulted in a lesser degree of blood pressure elevation. Reverse transcription–polymerase chain reaction analysis revealed that DOCA-salt treatment enhanced endothelin gene expression in LE rats but failed to do so in BB rats. These data indicate that vasopressin plays a critical role in modulating vascular structure and mechanics, as well as blood pressure, in DOCA-salt–induced hypertension. Moreover, these effects of vasopressin are in part mediated by enhancement of endothelin expression.


Key Words: deoxycorticosterone salt • vasopressin • vascular resistance • hypertrophy • endothelin • elastic modulus • rats, inbred BB




This article has been cited by other articles:


Home page
Arch Intern MedHome page
S. N. Thornton
Cold-Induced Dehydration Decreases Tissue Perfusion and Increases Blood Pressure
Arch Intern Med, June 22, 2009; 169(12): 1166 - 1167.
[Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
Z. Sun
Genetic AVP deficiency abolishes cold-induced diuresis but does not attenuate cold-induced hypertension
Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1472 - F1477.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. M. Pollock
Endothelin, Angiotensin, and Oxidative Stress in Hypertension
Hypertension, April 1, 2005; 45(4): 477 - 480.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
C. P. del Villar, C. J. G. Alonso, C. A. Feldstein, L. A. Juncos, and J. C. Romero
Role of Endothelin in the Pathogenesis of Hypertension
Mayo Clin. Proc., January 1, 2005; 80(1): 84 - 96.
[Abstract] [PDF]


Home page
HypertensionHome page
C. Cardillo, U. Campia, M. Iantorno, and J. A. Panza
Enhanced Vascular Activity of Endogenous Endothelin-1 in Obese Hypertensive Patients
Hypertension, January 1, 2004; 43(1): 36 - 40.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Q. Pu, M. F. Neves, A. Virdis, R. M. Touyz, and E. L. Schiffrin
Endothelin Antagonism on Aldosterone-Induced Oxidative Stress and Vascular Remodeling
Hypertension, July 1, 2003; 42(1): 49 - 55.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. Li, J. J. Galligan, G. D. Fink, and A. F. Chen
Vasopressin Induces Vascular Superoxide Via Endothelin-1 in Mineralocorticoid Hypertension
Hypertension, March 1, 2003; 41(3): 663 - 668.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
F. Z. Ammarguellat, P. O. Gannon, F. Amiri, and E. L. Schiffrin
Fibrosis, Matrix Metalloproteinases, and Inflammation in the Heart of DOCA-Salt Hypertensive Rats: Role of ETA Receptors
Hypertension, February 1, 2002; 39(2): 679 - 684.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Yu, V. Gopalakrishnan, T. W. Wilson, and J. R. McNeill
Endothelin antagonist reduces hemodynamic responses to vasopressin in DOCA-salt hypertension
Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2511 - H2517.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
E. L. Schiffrin
Role of Endothelin-1 in Hypertension
Hypertension, October 1, 1999; 34(4): 876 - 881.
[Abstract] [Full Text] [PDF]